mesenchymal stem cells - Tongji Hospital
Prolia (denosumab) - Amgen
fresolimumab (GC 1008) - Sanofi
Evenity (romosozumab-aqqg) - Astellas, Amgen, UCB
setrusumab (UX143) - Mereo Biopharma, Ultragenyx
Pathogenesis and precision management of osteogenesis imperfecta: from genetic mechanisms to novel therapies. (PubMed, World J Pediatr) - Oct 1, 2026 - "Integrating molecular diagnostics with robust genotype-phenotype correlations is essential for advancing personalized care. Future breakthroughs will rely on the translation of gene and cell therapies to ultimately improve the long-term clinical outcomes for patients with OI." 
Journal • Review • Gene Therapies • Genetic Disorders • Orthopedics • Otorhinolaryngology • COL1A1 • COL1A2
http://www.ncbi.nlm.nih.gov/pubmed/42814222
 
Bing-Yan Cao; Bing-Yu Yang; Cai Zhang; Hai-Yan Wei; Hong-Ying Wang; Li Wang; Qiong Chen; Ting Chen; Wei Wu; Wen-Li Lu; Xiao-Hong Sun; Xin Li; Xin-Yi Jiang; Xiu-Zhi Ren; Xue-Qian Wang; Yan Sun; Yao-Shuang Li; Zhe Su; Zhong-Hang Zhao
 
Oct 1, 2026
 
Prev Next